Jianmin Pharmaceutical Group Co Ltd (600976) - Total Assets
Based on the latest financial reports, Jianmin Pharmaceutical Group Co Ltd (600976) holds total assets worth CN¥4.34 Billion CNY (≈ $634.71 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Jianmin Pharmaceutical Group Co Ltd net assets for net asset value and shareholders' equity analysis.
Jianmin Pharmaceutical Group Co Ltd - Total Assets Trend (2001–2024)
This chart illustrates how Jianmin Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data.
Jianmin Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jianmin Pharmaceutical Group Co Ltd's total assets of CN¥4.34 Billion consist of 60.8% current assets and 39.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 3.8% |
| Accounts Receivable | CN¥983.33 Million | 23.0% |
| Inventory | CN¥354.31 Million | 8.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥50.98 Million | 1.2% |
| Goodwill | CN¥214.03K | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Jianmin Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jianmin Pharmaceutical Group Co Ltd (600976) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jianmin Pharmaceutical Group Co Ltd's current assets represent 60.8% of total assets in 2024, a decrease from 64.7% in 2001.
- Cash Position: Cash and equivalents constituted 3.8% of total assets in 2024, down from 35.6% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 5.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 23.0% of total assets.
Jianmin Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Jianmin Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.15 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs93.93 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.02 Billion |
Jianmin Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 1.57 | 1.42 |
| Quick Ratio | 1.40 | 1.38 | 1.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥963.30 Million | CN¥975.69 Million | CN¥445.44 Million |
Jianmin Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jianmin Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.97 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 2.6% |
| Total Assets | CN¥4.28 Billion |
| Market Capitalization | $710.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jianmin Pharmaceutical Group Co Ltd's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jianmin Pharmaceutical Group Co Ltd's assets grew by 2.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jianmin Pharmaceutical Group Co Ltd (2001–2024)
The table below shows the annual total assets of Jianmin Pharmaceutical Group Co Ltd from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.28 Billion ≈ $625.95 Million |
+2.63% |
| 2023-12-31 | CN¥4.17 Billion ≈ $609.90 Million |
+21.24% |
| 2022-12-31 | CN¥3.44 Billion ≈ $503.04 Million |
+21.66% |
| 2021-12-31 | CN¥2.83 Billion ≈ $413.47 Million |
+16.90% |
| 2020-12-31 | CN¥2.42 Billion ≈ $353.71 Million |
+25.34% |
| 2019-12-31 | CN¥1.93 Billion ≈ $282.21 Million |
+11.98% |
| 2018-12-31 | CN¥1.72 Billion ≈ $252.01 Million |
-10.50% |
| 2017-12-31 | CN¥1.92 Billion ≈ $281.56 Million |
+6.44% |
| 2016-12-31 | CN¥1.81 Billion ≈ $264.54 Million |
+12.84% |
| 2015-12-31 | CN¥1.60 Billion ≈ $234.43 Million |
+3.57% |
| 2014-12-31 | CN¥1.55 Billion ≈ $226.35 Million |
+7.02% |
| 2013-12-31 | CN¥1.45 Billion ≈ $211.51 Million |
+14.62% |
| 2012-12-31 | CN¥1.26 Billion ≈ $184.52 Million |
+7.94% |
| 2011-12-31 | CN¥1.17 Billion ≈ $170.95 Million |
+8.41% |
| 2010-12-31 | CN¥1.08 Billion ≈ $157.69 Million |
-16.86% |
| 2009-12-31 | CN¥1.30 Billion ≈ $189.66 Million |
+11.83% |
| 2008-12-31 | CN¥1.16 Billion ≈ $169.60 Million |
+30.86% |
| 2007-12-31 | CN¥885.70 Million ≈ $129.61 Million |
-15.79% |
| 2006-12-31 | CN¥1.05 Billion ≈ $153.91 Million |
-0.87% |
| 2005-12-31 | CN¥1.06 Billion ≈ $155.25 Million |
+14.76% |
| 2004-12-31 | CN¥924.49 Million ≈ $135.28 Million |
+73.57% |
| 2003-12-31 | CN¥532.62 Million ≈ $77.94 Million |
+17.36% |
| 2002-12-31 | CN¥453.85 Million ≈ $66.41 Million |
+13.91% |
| 2001-12-31 | CN¥398.42 Million ≈ $58.30 Million |
-- |
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells medicines in China. It provides medicines and pediatric drugs under the Jianmin, Longmu, and Yekaitai brand name. The company provides OTC, medical, and general health products, as well as consultation service. Jianmin Pharmaceutical Group Co.,Ltd. was founded in 1993 and is headquartered in Wuhan, China.